New hope for pancreatic cancer: drug combo aims to shrink tumors before surgery
NCT ID NCT07415525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called IBI343 combined with chemotherapy for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. The goal is to shrink the tumor enough so it can be surgically removed, then follow up with more chemo. About 40 participants will receive this treatment before and after surgery to see if it helps prevent the cancer from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Blood and gut clues may flag pancreatic cancer risk early
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- MRI might reveal hidden pancreatic risks in obesity
- Can a new PET tracer light up hidden cancers?
- Can a pill rouse the immune system against pancreatic cancer?